Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-jRCTs051200021
JPRN-jRCTs051200021
Recruiting
Phase 2

Phase II study to evaluate the efficacy and safety of the introduction of high-dose chemotherapy comprising thiotepa and melphalan to conventional chemoradiotherapy depending on new risk classification for medulloblastoma - JCCG MB19

Hara Junichi0 sites229 target enrollmentMay 28, 2020
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
Hara Junichi
Enrollment
229
Status
Recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 28, 2020
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Hara Junichi

Eligibility Criteria

Inclusion Criteria

  • •1\) Locally diagnosed as medulloblastoma after tumor resection or biopsy
  • •2\) Protocol treatment can be started within 6 weeks after surgery
  • •3\) Less than 30 years
  • •4\) No prior radiation or chemotherapy
  • •5\) ECOG Performance Status (PS) is 3 or less

Exclusion Criteria

  • •1\) Active double cancer (synchronous double cancer and metachronous double cancer with disease\-free period of 5 years or less).
  • •2\) Complicated with extracranial metastasis (M4\).
  • •3\) Complicated heart disease requiring treatment.
  • •4\) You are pregnant or nursing.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 2
Phase II study of multimodality treatment for ATRTAtypical teratoid rhabdoid tumorD016543
JPRN-jRCTs051200071Junichi Hara50
Not yet recruiting
Phase 2
Phase II study to evaluate the efficacy and safety of mirogabalin for CIPN in patients with gastrointestinal cancer.esophageal cancer, gastric cancer, small bowel cancer, colon cancer, pancreatic cancer
JPRN-UMIN000049555ational Cancer Center Hospital30
Recruiting
Phase 2
Evaluation of the efficacy of bioadhesive barrier-forming oral liquid gel (Episil) for prevention of oral mucositis
JPRN-jRCTs062220023Takano HIdeyuki50
Not yet recruiting
Phase 2
Study to examine the efficacy and safety of Awa Suzuka extracted ingredientsHealthy subjects with serum triglyceride levels in the borderline range
JPRN-UMIN000052759Tokushima University Graduate School40
Recruiting
Phase 2
Phase II study evaluating the efficacy and safety of the Bevacizumab / Docetaxel maintenance therapy beyond stable disease in patients with advanced relapsed non-squamous NSCLC who received Bevacizumab / pemetrexed / platinum induction therapy
JPRN-UMIN000010055Respiratory Center, Showa University Northern Yokohama Hospital20